Trulicity Market Size and Share
Trulicity Market Analysis by Mordor Intelligence
The Trulicity Market size was valued at USD 10.36 billion in 2026 and is estimated to grow from USD 11.35 billion in 2027 to reach USD 17.91 billion by 2032, at a CAGR of 9.55% during the forecast period (2027-2032).
The Centers for Disease Control (CDC) determined that COVID-19 was a serious public health threat for people with serious chronic diseases, including diabetes. People with diabetes were more likely to experience complications when infected with the virus. As per the American Diabetes Association, people with diabetes, if uncontrolled, had worse outcomes if infected with a virus such as COVID-19. The International Diabetes Federation explained that when people with diabetes develop a viral infection, it can be harder to treat due to fluctuations in blood glucose levels and diabetes complications as the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period.
Further, during the COVID-19 pandemic, many restrictions were imposed, putting people into lockdown, which led to contribution to obesity through unhealthy diets, physical inactivity, or highly sedentary behaviors. Further, these factors were associated with sustained weight gain and persisted even after lockdown restrictions were lifted. Weight management guidelines recommended a multi-component approach for weight loss in patients living with obesity and overweight. The use of anti-obesity medications was an effective option for weight control to improve the quality of life and prevent the progression of weight-related comorbidities.
Trulicity is an injectable diabetes medicine that helps control blood sugar levels. Trulicity is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also used to help reduce the risk of serious heart problems such as heart attack or stroke in adults who have type-2 diabetes and heart disease. It is used for adults and children 10 years of age and older with type-2 diabetes, along with diet and exercise to improve blood sugar.
Designed to reshape global care networks over the next decade, the 2022 World Health Assembly Resolution establishes a legally backed framework for systemic diabetes intervention. The mandate directs member countries to transition diabetes prevention and management directly into primary healthcare models while removing economic barriers to scale up universal insulin access. Structurally, it prioritises the international harmonization of regulatory policies for metabolic pharmaceuticals and monitoring tech, paired with modernized data surveillance frameworks.
Major factors that are expected to boost the growth of the studied market in the forecast period are rising obesity and inactivity rates among people, which have resulted in an increase in the diabetes population over time, a rise in the sedentary lifestyle, improper dietary patterns, and the inherent history of diabetes disorders. In addition, rising investment in research and development, technological developments, and new product launches will further provide potential opportunities for the growth of glucagon-like peptide 1 (GLP-1) agonists such as Trulicity in the coming years.
Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.
Market Trends and Insights
Rising obesity and diabetes prevalence globally
The diabetes population globally is expected to rise by 1.9% during the forecast period.
The major factors attributing to the growth of the market studied are an increase in obesity among people and a rising prevalence rate of type-2 diabetes and heart diseases. People with more fat in their bodies are highly likely to be affected by diabetes. For instance, as per the World Obesity Atlas 2023, the estimates for global levels of overweight and obesity (BMI ≥25kg/m²) suggest that over 4 billion people may be affected by 2035. The prevalence of obesity (BMI ≥30kg/m²) alone is anticipated to rise to 24% of the population over the same period, affecting nearly 2 billion adults, children, and adolescents by 2035.
Additionally, according to the World Health Organization (WHO) May 2022 report on the European region, in the WHO European Region, over 60% of adults and 29% of boys and 27% of girls who are children are overweight or obese and also, as per the same report, overweight and obesity rank fourth among the risk factors for non-communicable diseases in the region, after high blood pressure, unhealthy eating, and cigarette use. Furthermore, according to the latest International Diabetes Federation report, it is estimated that the number of adults in the age group of 20-79 years across the world is projected to increase to 643 million by 2030. Hence, owing to the high burden of obesity and the increasing prevalence of risk factors for obesity are expected to fuel the market growth over the forecast period.
North America held the highest market share in the current year
Over the past twenty years, diabetes rates across North America have surged. This upward trajectory is primarily fueled by climbing obesity rates alongside modern lifestyle shifts, including poor dietary habits and reduced daily physical activity.
According to updated data from the Centers for Disease Control and Prevention (CDC), the burden in the United States has escalated to more than 155 million adults living with the condition; this includes 40.1 million individuals diagnosed or undiagnosed with diabetes, and an additional 115.2 million dealing with prediabetes. The vast majority of these cases are type 2 diabetes. Furthermore, the impact of the disease remains deeply unequal, hitting hardest among communities of color, individuals in rural environments, and populations facing lower income levels, limited education, and restricted health literacy. Therefore, the studied market is anticipated to grow over the analysis period due to the rising prevalence and the factors above.
Competitive Landscape
Market Concentration
The Trulicity Market is consolidated with no generic products.
Trulicity Industry Leaders
-
Eli Lilly
- *Disclaimer: Major Players sorted in no particular order
Trulicity Market Companies Covered in this Report
- Eli Lilly and Company
Recent Industry Developments in Trulicity Market
- November 2023: Eli Lilly New Zealand expected limited availability of the type-2 Diabetes (T2D) medication Trulicity (dulaglutide) due to global supply pressure. The company is focused on maintaining supplies of Trulicity in New Zealand for existing patients. The supply situation is expected to continue to remain dynamic until the end of 2024. During this time, patients in New Zealand may experience delays or interruptions in fulfilling their Trulicity prescriptions.
- July 2023: Eli Lilly has informed the Therapeutic Goods Administration (TGA) that the limited availability of Trulicity (dulaglutide) will be extended to 31 December 2024, in line with a similar notification for Ozempic (semaglutide).
Global Trulicity Market Report Scope
Trulicity (Dulaglutide) is a medication used for the treatment of type-2 diabetes in combination with diet and exercise. The Trulicity market is segmented by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America).
The report offers the value (in USD) and volume (in Units) for the above segments.
Segmentation Overview
| North America | United States |
| Canada | |
| Rest of North America | |
| Europe | Germany |
| Spain | |
| Italy | |
| France | |
| United Kingdom | |
| Russia | |
| Rest of Europe | |
| Asia-Pacific | Japan |
| China | |
| Australia | |
| India | |
| South Korea | |
| Malaysia | |
| Indonesia | |
| Thailand | |
| Philippines | |
| Vietnam | |
| Rest of Asia-Pacific | |
| Latin America | Brazil |
| Mexico | |
| Rest of Latin America | |
| Middle East and Africa | South Africa |
| Saudi Arabia | |
| Oman | |
| Egypt | |
| Iran | |
| Rest of Middle East and Africa |
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Europe | Germany | |
| Spain | ||
| Italy | ||
| France | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Asia-Pacific | Japan | |
| China | ||
| Australia | ||
| India | ||
| South Korea | ||
| Malaysia | ||
| Indonesia | ||
| Thailand | ||
| Philippines | ||
| Vietnam | ||
| Rest of Asia-Pacific | ||
| Latin America | Brazil | |
| Mexico | ||
| Rest of Latin America | ||
| Middle East and Africa | South Africa | |
| Saudi Arabia | ||
| Oman | ||
| Egypt | ||
| Iran | ||
| Rest of Middle East and Africa | ||
Key Questions Answered in the Report
How big is the Trulicity Market?
The Trulicity Market size is expected to reach USD 10.36 billion in 2026 and grow at a CAGR of greater than 9.55% to reach USD 17.91 billion by 2032.
What is the current Trulicity Market size?
In 2027, the Trulicity Market size is expected to reach USD 11.35 billion.
Who are the key players in Trulicity Market?
Eli Lilly are the major companies operating in the Trulicity Market.
Which is the fastest growing region in Trulicity Market?
North America is estimated to grow at the highest CAGR over the forecast period (2027-2032).
Which region has the biggest share in Trulicity Market?
In 2026, the North America accounts for the largest market share in Trulicity Market.